After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Ozempic and other similar drugs must be injected. Messer describes the needle as “small, the size of two human hairs.” ...

Even as Singapore attempts to revive its stock market, and despite challenging exits, private equity continues to flourish ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Utz Brands Inc. said recent tariffs will likely not affect the company and the cost of manufacturing its snacks, but it is ...

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...